Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Illumina (ILMN) shares fell on Friday after its chief commercial officer, Everett Cunningham, resigned to lead the rival life ...

Nearly a year after leaving his position as longtime director of the National Human Genome Research Institute (NHGRI), Eric ...

If you are wondering whether Illumina's current share price offers fair value or room for mispricing, you are not alone. This article walks through what the numbers actually say about the stock.

During the meeting, Steve Barnard, PhD, Illumina’s CTO will provide new details about the company’s constellation mapped read technology. He will be joined by Niall Lennon, PhD, chair and CSO of Broad ...

A streamlined, automated process helps scientists coordinate site-ready production-level whole genome sequencing results.

Illumina, Inc. has announced that scientists at the Company have sequenced the genome of an anonymous African male (Yoruba from Ibadan, Nigeria), using the Genome Analyzer. Sequencing of this HapMap ...

Illumina, San Diego’s DNA-sequencing giant, has a new boss. Illumina’s board tapped Jacob Thaysen, a seasoned life science executive, to lead the $25 billion biotechnology company starting on Sept. 25 ...

The Chinese government took its economic sanctions against San Diego-based Illumina a step further Tuesday by banning the gene-sequencing company from importing its machines to the country. It’s part ...

Gene-sequencing company Illumina ILMN2.06%increase; green up pointing triangle said Sunday it will divest itself of cancer blood test maker Grail, following Illumina’s loss in its legal battle against ...